Standigm will create advanced AI models using Nashville Biosciences’ de-identified genomic and clinical data. The data sets will help identify therapeutic targets, accelerate treatment development and improve patient outcomes, according to an Aug. 10 press release from Standigm.
The models are meant to assist with accelerating early-stage drug discovery and understanding the relationship between genetic variants and corresponding phenotypes. Additionally, incorporating large-scale data into the AI platforms will allow Standigm customers to leverage data of interest without collecting the data themselves.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
